SINOVAC Omicron-specific vaccine approved for clinical trial in Hong Kong

Excerpt:

Sinovac Biotech Ltd. (“SINOVAC”) has received approval for a clinical trial of their inactivated COVID-19 vaccine (Omicron strain) in Hong Kong, China.

Article Summary

Sinovac Biotech Ltd. (“SINOVAC”) has received approval for a clinical trial of their inactivated COVID-19 vaccine (Omicron strain) in Hong Kong, China.

During the year 2021, SINOVAC continued to work on COVID-19 vaccines targeting the Gamma and Delta strains. When the Omicron variant was first reported to WHO on November 24, SINOVAC acted fast to secure the strain by early December, promoting development and preclinical testing that has shown the vaccine to be safe and efficacious in animals.

SINOVAC began submitting clinical applications for its Omicron-specific COVID-19 vaccine to nations and regions around the world in February 2022. The SINOVAC Omicron strain inactivated vaccine has received its first clinical approval in Hong Kong. SINOVAC will continue to work closely with international partners to advance research on its COVID-19-based vaccination against developing variants, as well as clinical trials on sequential immunisation of new variant strain vaccines to assess their safety and efficacy.

Source: Sinovac

Comments

Leave A Comment

Leave a Reply

Your email address will not be published.

bag